News

Novacyt expands development partnership with Immunexpress

Extension of contract continues multi-year assay design and development program Paris, France and Camberley, UK – 8 April 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has expanded its assay development contract with Immunexpress, Inc. (Immunexpress), a U.S.-based molecular diagnostic company with the first FDA cleared host response test for suspected sepsis patients, to further support the development of rapid diagnostic assays for the detection [...]

Read more...
International Animal Rescue q16

International Animal Rescue to use Primerdesign genesig q16 and selected assays

Paris, France and Camberley, UK – 26 February 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that through its molecular testing subsidiary, Primerdesign, it has reached a supply agreement with International Animal Rescue. International Animal Rescue will use the Primerdesign genesig q16 real-time PCR instrument to test Orangutans, rescued in Indonesia, for a variety of diseases including plasmodium. Primerdesign will also undertake additional development work to tailor specific assays for testing Orangutans during [...]

Read more...

Novacyt launches two new CE-IVD Marked molecular diagnostic kits

First of an expanding menu of tests for monitoring post-transplantation and immunosuppressed patients Paris, France and Camberley, UK – 21 December 2018: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces the launch of its next CE-Marked approved molecular products, the genesig® Real-Time PCR BK virus (BKV) Kit (CE) and genesig® Real-Time PCR Epstein-Barr Virus (EBV) Kit (CE). These clinical products follow the launch of a Zika assay in the second half of 2017 and [...]

Read more...

Completion of substantial q16 molecular diagnostics order

Completion of substantial q16 molecular diagnostics order expands clinical diagnostic reach in fast growing Chinese market Paris, France and Camberley, UK – 6th December 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has received another substantial order for Primerdesign’s q16 molecular instruments from a new customer within the fast growing Chinese market. The order for 100 molecular diagnostic instruments has been paid in advance and takes the number of q16 instruments sold [...]

Read more...

NOVACYT PARTNERS WITH APPLIED MICROARRAYS IN ASSAY DESIGN

US partnership to facilitate the design and optimisation for customised microarray assays Paris, France and Camberley, UK – 13 September 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has partnered with Applied Microarrays, Inc. (AMI), a company that specialises in providing customised microarrays and manufacturing point-of-care (POC) and high throughput DNA and protein arrays, to offer comprehensive single nucleotide polymorphism (SNP) assay development. Primerdesign will play [...]

Read more...

The Primerdesign Sweet Shop is Closing

As many of you in the UK will be aware, Primerdesign have been running our very own sweet shop, Primersweets, since 2013. Each order that we mail out includes a voucher which can be redeemed for a selection of sweets. This was created as a little way of saying thank you to our UK customers for your business and support. The sweet shop was run virtually by our good friend, Dr Oligoo-Nucleotreat. He served the Primerdesign customers very well, but [...]

Read more...

Novacyt Announces Acquisition of Infectious Disease Business from Omega Diagnostics

Accelerating profitability by expanding the Lab21 business with complimentary products Paris, France and Camberley, UK – 28th June 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that its protein diagnostics division, Lab21 Products (Lab21), has unconditionally entered into an asset purchase agreement to acquire the Infectious Disease (ID) business from Omega Diagnostics Ltd (AIM: ODX, “Omega Diagnostics”), for an initial consideration of £1.8 million, up to £2.175 million in total, [...]

Read more...